Financial Performance - The company's revenue for the year reached RMB 40,340.8 million, an increase from RMB 39,354.8 million in the previous year, representing a growth of 2.5%[12] - Adjusted net profit attributable to the parent company was RMB 10,854.6 million, up from RMB 9,399.3 million, reflecting a growth of 15.5%[12] - Gross profit margin improved to 40.6%, compared to 36.9% in the previous year, indicating enhanced profitability[12] - The total assets of the company increased to RMB 73,669.3 million from RMB 64,690.3 million, marking a growth of 13.7%[12] - The company achieved a net profit margin of 26.5%, up from 22.4% in the previous year, showcasing improved operational efficiency[12] - Basic earnings per share rose to RMB 3.64 from RMB 3.01, reflecting a growth of 21%[12] - The company achieved a revenue of RMB 40,340.8 million, representing a year-on-year growth of 2.5%, and a net profit attributable to shareholders of RMB 10,690.2 million, up 21.3% year-on-year[14] - Gross profit for 2023 was RMB 16.37 billion, an increase of 12.9% compared to 2022, with a gross margin of 40.6%[27] - Operating profit increased to RMB 13,190,743 thousand in 2023, with an operating margin of 32.7%, compared to 27.5% in 2022[114] - Net profit attributable to shareholders for 2023 was RMB 10,690,153 thousand, reflecting a net profit margin of 26.5%, up from 22.4% in 2022[114] Customer Engagement and Market Expansion - The company added over 1,200 new customers in 2023, with active customers exceeding 6,000, and the order backlog, excluding COVID-19 commercialization projects, grew by 18% year-on-year[15] - Revenue from U.S. customers reached RMB 26.13 billion, a 42% increase year-on-year when excluding COVID-19 projects; revenue from European customers was RMB 4.70 billion, up 12%[15] - The company’s revenue from the top 20 global pharmaceutical companies reached RMB 16.11 billion, a 44% increase year-on-year when excluding COVID-19 projects[15] - The company’s revenue from existing customers accounted for 98% of total revenue, amounting to RMB 39.63 billion, with a 30% increase year-on-year when excluding COVID-19 projects[15] - The company is focused on developing new drug types such as peptides, oligonucleotides, and PROTACs to capture emerging business opportunities[66] Operational Efficiency and Capacity Expansion - The company completed capacity expansion projects in Changzhou and Taixing, with new capacity operational in January 2024, increasing the volume of peptide solid-phase synthesis reactors to 32,000L[18] - The company is expanding its capacity with new facilities totaling 55,000 square meters in Suzhou and Qidong, enhancing operational efficiency[68] - The new raw material drug production base in Taixing officially commenced partial operations in January 2024, supporting ongoing business growth[68] Financial Management and Investments - The debt-to-asset ratio decreased to 24.6% from 27.5%, indicating a stronger financial position[12] - The net cash used in investing activities for 2023 was RMB 6,817.0 million, a decrease of 26.8% compared to 2022, primarily due to timing differences in project settlements leading to reduced capital expenditures[38] - The net cash used in financing activities for 2023 was RMB 3,939.2 million, an increase of 210.0% compared to 2022, mainly due to increased cash dividend payments and repayment of bank loans during the reporting period[38] - The company has strategically focused on investments that support its existing value chain and promote advancements in the pharmaceutical and healthcare sectors[55] Governance and Leadership - The board consists of 12 members, including 5 executive directors, 2 non-executive directors, and 5 independent non-executive directors[116] - The company has a strong leadership team with diverse backgrounds in pharmaceutical and financial sectors[116] - The management team possesses extensive experience in the pharmaceutical industry, enabling the company to quickly adapt to market trends and customer needs[71] - The company emphasizes its commitment to innovation and strategic growth in the pharmaceutical industry[116] Risk Management - The company faces risks from potential declines in demand for pharmaceutical research services, which could negatively impact business if industry trends slow down or outsourcing ratios decrease[99] - The company is exposed to risks from changes in regulatory policies in the pharmaceutical research services industry, which could adversely affect operations if it fails to adjust its strategies accordingly[100] - The company has established a relatively complete internal control system to ensure compliance with laws and regulations, but faces risks if oversight of subsidiaries is insufficient[103] Future Outlook - The company expects 2024 revenue to reach RMB 38.3 billion to RMB 40.5 billion, with a growth rate of 2.7% to 8.6% excluding COVID-19 commercialization projects[24] - The company aims to build an integrated enabling platform to support innovation in the pharmaceutical industry, allowing any individual or company to realize their innovation dreams[90] - Future outlook indicates a projected revenue growth of 25% for the next fiscal year, driven by new product launches and market expansion strategies[128] Corporate Social Responsibility - The company is committed to enhancing customer stickiness and increasing customer conversion rates while continuously expanding its customer base[89] - The company aims to improve customer satisfaction through high-quality services and strict intellectual property protection, while expanding its global customer base, particularly targeting long-tail customers[93] - The company has not encountered any non-compliance cases related to bribery and corruption as of December 31, 2023, following anti-corruption training and initiatives[188]

FF304 翌日披露報表 (股份發行人 ── 已發行股本變動及/或股份購回) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 FF304 呈交日期： 2024年4月25日 | | 變動日期 2024年3月13日 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 4). | 購回股份(或其他證券)但沒有註銷 | 373,500 | 0.01 % | RMB | 53.81 RMB | 56.75 | -5.1806 % | | | 於2024年3月14日，本公司回購373,500股A股股份。 | | | | | | | | | 變動日期 2024年3月14日 | | | | | | | | 5). | 購回股份(或其他證券)但沒有註銷 | 387,900 | 0.02 % | RMB | 51.81 RMB | 53.51 | -3.177 % | | | 於2024年3月15日，本公司回購387,900股A股股份。 | | | | | | | | | 變動日期 2024年3月15日 | | | | ...

公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2024年4月24日 FF304 翌日披露報表 (股份發行人 ── 已發行股本變動及/或股份購回) 表格類別： 股票 狀態： 新提交 | 第一章節 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | 於香港聯交所上市(註11) | 否 | | | | | | | 於上海證券交易所上市 | 證券代號 (如於香港聯交所上市) | 說明 | | | | | | | | | | 已發行股份佔 | 有關股份發行前的 | 上一個營業日 | 發行價較市值的折讓/ | | | | | | | | | 發行股份 | 每股發行價 | 股份數目 | 現有已發行股份數目 | 的每股收市價 | 溢價幅度(百分比) | (註6及7) | (註1及7) | | | | | 百分比 | (註5) | (註7) | (註4、6及7) | | | | | | | | | 於下列日期開始時的結存(註2) | ...

公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2024年4月23日 | 第一章節 | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | A | | | | 於香港聯交所上市(註11) | | 否 | | | | 證券代號 (如於香港聯交所上市) | | | 說明 | | 於上海證券交易所上市 | | | | | | | | | | | 發行股份 (註6及7) | 股份數目 | | 已發行股份佔 有關股份發行前的 現有已發行股份數目 百分比 (註4、6及7) | | 每股發行價 (註1及7) | | | 上一個營業日 的每股收市價 (註5) | 發行價較市值的折讓/ 溢價幅度(百分比) (註7) | | | | 於下列日期開始時的結存(註2) | 2024年4月22日 | | 2,546,260,847 | | | | | | | | | | 1). | 購回股份(或其他證券)但沒有註銷 | ...

FF304 翌日披露報表 (股份發行人 ── 已發行股本變動及/或股份購回) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2024年4月22日 | 第一章節 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | 於香港聯交所上市(註11) | 否 | | | | | | | 證券代號 (如於香港聯交所上市) | 說明 | 於上海證券交易所上市 | | | | | | | | | | 已發行股份佔 | 有關股份發行前的 | 上一個營業日 | 發行價較市值的折讓/ | | | | | | | | | 發行股份 | 每股發行價 | 股份數目 | 現有已發行股份數目 | 的每股收市價 | 溢價幅度(百分比) | (註6及7) | (註1及7) | | | | | 百分比 | (註5) | (註7) | (註4、6及7) | | | | | | | | | 2,546,260,847 | 於 ...

FF304 翌日披露報表 (股份發行人 ── 已發行股本變動及/或股份購回) 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2024年4月19日 | 第一章節 | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | | | | 於香港聯交所上市(註11) | 否 | | | | | 證券代號 (如於香港聯交所上市) | | 說明 | | 於上海證券交易所上市 | | | | | | | | | | | 發行股份 (註6及7) | 股份數目 | | 已發行股份佔 有關股份發行前的 現有已發行股份數目 百分比 (註4、6及7) | | | 每股發行價 (註1及7) | | 上一個營業日 的每股收市價 (註5) | | 發行價較市值的折讓/ 溢價幅度(百分比) (註7) | | | 於下列日期開始時的結存(註2) | 2024年4月18日 | | 2,546,260,847 | | | | ...

FF304 翌日披露報表 (股份發行人 ── 已發行股本變動及/或股份購回) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2024年4月18日 | 第一章節 | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | A | | | | 於香港聯交所上市(註11) | | 否 | | | | 證券代號 (如於香港聯交所上市) | | | 說明 | | 於上海證券交易所上市 | | | | | | | | | | | 發行股份 (註6及7) | 股份數目 | | 已發行股份佔 有關股份發行前的 現有已發行股份數目 百分比 (註4、6及7) | | 每股發行價 (註1及7) | | | 上一個營業日 的每股收市價 (註5) | 發行價較市值的折讓/ 溢價幅度(百分比) (註7) | | | | 於下列日期開始時的結存(註2) | 2024年4月17日 | | 2, ...

公司名稱： 無錫藥明康德新藥開發股份有限公司 FF304 翌日披露報表 (股份發行人 ── 已發行股本變動及/或股份購回) 表格類別： 股票 狀態： 新提交 呈交日期： 2024年4月17日 | 第一章節 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | 否 | 於香港聯交所上市(註11) | | | | | | | 於上海證券交易所上市 | 證券代號 (如於香港聯交所上市) | 說明 | | | | | | | | | | 已發行股份佔 | 有關股份發行前的 | 上一個營業日 | 發行價較市值的折讓/ | | | | | | | | | 發行股份 | 每股發行價 | 股份數目 | 現有已發行股份數目 | 的每股收市價 | 溢價幅度(百分比) | (註6及7) | (註1及7) | | | | | 百分比 | (註5) | (註7) | (註4、6及7) | | | | | | | | | 於下列日期開始時的結存(註2) | ...

FF304 翌日披露報表 (股份發行人 ── 已發行股本變動及/或股份購回) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2024年4月16日 | 第一章節 | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | | | | 於香港聯交所上市(註11) | 否 | | | | | 證券代號 (如於香港聯交所上市) | | 說明 | | 於上海證券交易所上市 | | | | | | | | | | | 發行股份 (註6及7) | 股份數目 | | 已發行股份佔 有關股份發行前的 現有已發行股份數目 百分比 (註4、6及7) | | | 每股發行價 (註1及7) | | 上一個營業日 的每股收市價 (註5) | | 發行價較市值的折讓/ 溢價幅度(百分比) (註7) | | | 於下列日期開始時的結存(註2) | 2024年4月15日 | | 2,54 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 董事長 李革博士 香港，2024年4月15日 於本公告日期，董事會包括執行董事李革博士、陳民章博士、胡正國先生、楊青博士及 張朝暉先生；非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛 博士、張新博士、詹智玲女士及馮岱先生。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 董事會會議召開日期 無錫藥明康德新藥開發股份有限公司（「本公司」，連同其子公司「本集團」）董 事會（「董事會」）謹此宣佈將於2024年4月29日（星期一）召開董事會會議，以考 慮及批准（其中包括）本集團截至2024年3月31日止三個月之第一季業績及其發佈。 承董事會命 無錫藥明康德新藥開發股份有限公司 * 僅供識別 ...